TOKYO MEDICAL AND DENTAL UNIVERSITY IMAGE: TOP, SETD1A, DIRECTLY RECRUITED TO THE RUVBL1 PROMOTER, ENHANCES RUVBL1 GENE EXPRESSION BY INCREASING H3K4ME3 LEVELS IN PANCREATIC CANCER CELLS. BOTTOM, HIGH CO-EXPRESSION OF SETD1A AND RUVBL1 CAN PREDICT WORSE PROGNOSIS THAN OTHERS. CREDIT: DEPARTMENT OF MOLECULAR ONCOLOGY, TMDU Researchers from Tokyo Medical and Dental University (TMDU) uncover an...
by Brigham and Women’s Hospital Credit: Wikimedia Commons Elevated blood pressure can cause a condition known as perivascular fibrosis, where the outside wall of a blood vessel thickens due to connective tissue build-up. Although recent data has suggested that the thickening is due to the activation of T-cells, the defenders of our immune system, the...
by La Jolla Institute for Immunology Parkinson’s disease is not usually seen as an autoimmune disease. Credit: Leterrier, NeuroCyto Lab, INP, Marseille, France Scientists at La Jolla Institute for Immunology (LJI) have found that people with Parkinson’s disease have a clear “genetic signature” of the disease in their memory T cells. The scientists hope that...
MASSACHUSETTS INSTITUTE OF TECHNOLOGY CAMBRIDGE, MA — Over the past decade, scientists have been exploring vaccination as a way to help fight cancer. These experimental cancer vaccines are designed to stimulate the body’s own immune system to destroy a tumor, by injecting fragments of cancer proteins found on the tumor. So far, none of these...
by Allessandra Dicorato, Broad Institute of MIT and Harvard Credit: Susanna Hamilton, Broad Communications Peptides encoded by unexplored regions of the SARS-CoV-2 genome provoke strong immune responses compared to other known peptides. Current COVID-19 vaccines are effective at preventing severe disease, including infection caused by known variants of concern. But new variants of the SARS-CoV-2 virus...
by John Hewitt , Medical Xpress Credit: R. Salgia et. al., Cell Reports Medicine (2021). DOI: 10.1016/j.xcrm.2020.100186 The growth of solid tumors is frequently driven by mutations in key proto-oncogenes. For non-small-cell lung cancers (NSCLC), somatic mutations in the KRAS (Kirsten RAt Sarcoma virus) gene turn it into an oncogene that renders tumors resistant to common chemotherapies...
